Author Archives: Scalper1

What’s Ailing Biotech?

Summary Concerns about profitability and valuations had already infected US biotechnology stock prices in September. Increased political and media attention on rising drug costs sent the sector deeper into a decline. Evan McCulloch shares his insights on the drug-cost debate, presidential candidate Hillary Clinton’s proposal, and the fallout on the biotech sector at large. Evan McCulloch Senior Vice President, Director of Research Franklin Equity Group® Portfolio Manager, Franklin Biotechnology Discovery Fund (MUTF: FBDIX ) ________________________________________________________ We have seen some turmoil in the biotech sector over the last few weeks. What’s been driving this volatility? There’s been some volatility in the equity market at large, which has resulted in investor skittishness overall and a hypersensitivity to potential fundamental concerns. Specifically for the biotechnology sector, however, the threat of heightened scrutiny of drug prices has reared its head again. It started with an article in The New York Times on September 20 about a small private company called Turing Pharmaceuticals 1 that raised the price of an anti-toxoplasmosis drug it had acquired by 5,000%. This is very unusual for an older drug, so it was a case the media latched on to. The article was followed by a tweet from Democratic presidential candidate Hillary Clinton, indicating she thought some drug prices were excessive and that she had a plan to reduce prescription drug costs. Clinton subsequently announced her plan, which proposed that Medicare leverage its buying power to negotiate directly with drug companies. After that, other politicians jumped on the bandwagon and railed against high drug prices. The House Committee on Oversight and Reform already had been seeking to subpoena documents relating to Valeant Pharmaceuticals’ 2 price increases earlier this year on a pair of cardiovascular drugs, and it then asked to subpoena Turing Pharmaceuticals about the price increase on its drug, which treats parasitic infections. It’s interesting to note that the pricing noise has been around for a while; there have been a series of press articles on the subject going back to July. President Obama has made periodic comments about high drug prices, and Senator Bernie Sanders, who also is vying for the Democratic presidential nomination, released a plan focused on pricing which generated renewed attention. So while this is an issue that bears watching, I think it’s a culmination of sector-specific concerns about drug pricing on top of some broader market issues that has caused recent volatility in share prices. So where could this all be going? Might it result in a reduction in drug prices, in your opinion? For better or for worse, in my view the answer is no. All Clinton did was articulate a plan; it is not legislation. The price of prescription drugs is a popular topic because most people in the United States think drug prices are high, and it’s an issue that resonates well with voters. Again, this is not legislation, and if it were, it would not likely be approved by a Republican-majority Congress. Given that the Republicans seem likely to retain their majority in the House of Representatives after the 2016 election, I don’t believe any legislation can pass until 2018 at the earliest. Even if Clinton’s plan, as we currently understand it, did ultimately pass, in my view the impact would be very manageable for the sector. Most notably, according to our estimates, any cut to drug prices inside the Medicare program would be far less than the recent 15%-20% stock correction in the sector might imply. However, we do expect more market-based reforms. This public shaming process that politicians are employing will likely cause companies to moderate price increases going forward and also empower insurance companies to drive toward higher rebates and more substitution of cheaper drugs. So, we do expect some growth moderation at the margin, but it will probably be imperceptible at a sector level. In the fund, we focus on investing in companies with drugs that deliver strong clinical value and have limited competition, which seeks to mitigate the impact of some of these initiatives. Moving on to the topic of patent protection, do you have any concerns about the exclusivity provisions offered in the Trans-Pacific Partnership ( TPP ), the proposed trade agreement between 12 Pacific Rim countries? No, I don’t have any concerns about it. The TPP proposes that drugs sold outside the United States get eight years of exclusivity. Patents currently don’t protect US drugs overseas. So, granted, eight years is lower than the current 12 years of exclusivity in the United States, but eight years should be compared to virtually no exclusivity right now, as many of the countries covered in that partnership do not honor intellectual property rights. So, this provision would protect pharmaceutical companies for eight years, which would actually be a positive for the sector, in our opinion. What do you think the media is either not covering or may be misreporting about the biotech sector that you think investors should know? The media has focused on gross price increases on drugs, and that is very different from actual price increases or net price increases. In most cases, price increases are moderated through rebates to the payers, but since that’s a negotiated price, the actual price being paid by insurance plans to the drug companies is not transparent to investors or the media. In most cases, when we see a price increase, we know only about one-third to two-thirds of that price increase is realized, so the actual price increases are much lower than what is being reported in the press right now. What is your current outlook for the biotechnology space? I think fundamentals in the biotechnology sector are as strong as ever. In our view, the sector’s new-product pipeline is full, and important new treatments are advancing for cancer, Alzheimer’s dementia, and a whole range of rare genetic diseases. In cancer treatment, interest is very high in using drugs that harness the immune system to fight tumors. A number of new drug discovery technologies, like gene therapy, RNAi (RNA interference) and antisense, allow companies to target rare genetic diseases that were previously untreatable with more traditional drug approaches. For drugs that make it through the clinical trials process, the US Food and Drug Administration is working cooperatively with the sector to bring new drugs to patients, and in most situations has approved drugs that have strong value propositions for patients. Until recently, investor concern was generally constrained to stock valuations, not fundamentals. Although concerns about drug pricing power have arisen, I don’t expect any major change. And with more attractive valuations following this recent correction, we think the outlook for the sector is very positive. To get insights from Franklin Templeton Investments delivered to your inbox, subscribe to the Beyond Bulls & Bears blog. For timely investing tidbits, follow us on Twitter @FTI_US and on LinkedIn . This information is intended for US residents only. Evan McCulloch’s comments, opinions and analyses are for informational purposes only and should not be considered individual investment advice or recommendations to invest in any security or to adopt any investment strategy. Because market and economic conditions are subject to rapid change, comments, opinions and analyses are rendered as of the date of the posting and may change without notice. The material is not intended as a complete analysis of every material fact regarding any country, region, market, industry, investment or strategy. What Are the Risks? F ranklin Biotechnology Discovery Fund All investments involve risks, including possible loss of principal. The fund is a non-diversified fund that concentrates in a single sector, which involves risks such as patent considerations, product liability, government regulatory requirements, and regulatory approval for new drugs and medical products. Biotechnology companies often are small and/or relatively new. Smaller companies can be particularly sensitive to changes in economic conditions and have less certain growth prospects than larger, more established companies and can be volatile, especially over the short term. The fund may also invest in foreign companies, which involve special risks, including currency fluctuations and political uncertainty. These and other risks are described more fully in the fund’s prospectus. Investors should carefully consider a fund’s investment goals, risks, sales charges and expenses before investing. To obtain a summary prospectus and/or prospectus, which contains this and other information, talk to your financial advisor, call us at (800) DIAL BEN®/342-5236 or visit franklintempleton.com. Please carefully read a prospectus before you invest or send money. _________________________________________________________________ 1. As of 9/30/2015, Turing Pharmaceuticals was not a holding of Franklin Biotechnology Discovery Fund. Holdings are subject to change without notice. 2. As of 9/30/2015, Valeant Pharmaceuticals was not a holding of Franklin Biotechnology Discovery Fund. Holdings are subject to change without notice.

Introducing The Tech-Focused Home Run Fund

This is a new portfolio project I’m working on targeting high-growth names in areas of the market I don’t typically invest in. Capital gains are the goal here, as opposed to my usual pursuit of income. I’m using this project to expand my investing horizons. This project started last Friday. Since then I’ve made 7 purchases worth roughly 21% of the fund’s starting value. I am pleased to introduce a new project I’ve started working on, a model portfolio that I’m in the process of building that I’ll call The Home Run Fund . This “fund” is a hypothetical portfolio that I manage and update in real-time focused around “owning” more high risk/high reward, speculative, momentum-driven, exciting companies in search of Alpha with a more short-term, trader-oriented mindset. I wonder sometimes how many other more traditional, conservative, buy and hold type dividend growth investors frequent other areas of this site – window shopping? I’m talking about technology, entertainment, media, biotech and the like that offer much higher growth potential than the typical blue chip, dividend aristocrat type companies that DGI portfolios are usually comprised of. These sections of Seeking Alpha are ones that I frequent as a reader, but don’t often contribute to as a writer. With the creation of this model portfolio series, I hope to change this. In my personal portfolios, I’m very satisfied chocking up on the bat, shortening my stroke, and hitting for average (and collecting those dividends). However, in this portfolio project I will be swinging for the fences. If you can’t tell, I’m a baseball fan. So, there we have it: The Home Run Fund . If you already follow me here , by now you have a pretty good idea about my investment philosophies and stock picking strategy. For those of you who aren’t as familiar with my work on Seeking Alpha, in the most basic sense, I would describe myself as a conservative dividend growth investor with a mind to buy and hold because of my very long-term investment horizon. I have exposure to some of these generally more risky sectors and industries in my personal portfolios; however, for the most part this exposure comes in the form of mature, mega/large cap “legacy” type companies. I focus on wide moats. I focus on strong, reliable cash flows and balance sheet health. More than anything, I am risk averse with capital preservation existing right at the top of my priority list alongside dividend growth. This sort of investing strategy has led to success for me, though I admit it can be lacking in the excitement department. Now obviously, excitement isn’t the name of the game when it comes to investing, making money is. However, I don’t think the two have to be mutually exclusive. This series will allow me to delve into a more risk-laden area of the market, a journey I am pleased to embark on because oftentimes, when it comes to the portfolio guidelines I’ve laid out for myself with regard to capital preservation and a conservative focus on value rather than growth, I find myself having to suppress urges to join in on the fun, exposing myself to some of the popular market darling stocks and their highly speculative valuations. I am not a professional in the financial industry. I manage a vineyard and work as a real estate agent. Portfolio management is a passion of mine; it’s rare that I make it through a day now without wishing that I had studied finance at the university level rather than English and Studio Art. Don’t get me wrong, I loved my time at the University of Virginia and the liberal arts education that I pursued. However, the degrees that I earned don’t qualify me to work in the industry that I currently love – it wasn’t until after graduation that I discovered the stock market and began managing money seriously. I say all of this for several reasons. First, to tamper down any unrealistic expectations. Although I plan on making more speculative bets that will lead to exorbitant gains in this portfolio comprised of hypothetical money, no one should be following my advice here as I admit wholeheartedly that I am a newbie when it comes to investing in high growth/non-dividend paying names. Taking this notion a step forward, no one should ever blindly follow me into or out of any trade; feel free to critique me, laugh at me, or learn with me, but don’t follow my lead without doing your own due diligence. This leads me to the second reason I highlighted my amateur status: to really highlight the point of this series and The Home Run Fund , which is, of course, education. Everything that I write related to finance is for educational purposes. Organizing my thoughts and putting them down onto paper forces me to look for weak spots in my ideas, for holes in my arguments. And once an article in completed, any comments that the piece inspires go on to further magnify my convictions and concerns, allowing me (and hopefully others as well) to take a step back and really digest the information, erasing doubts, and strengthening beliefs about stock picks and the evaluation process. I was recently at a real estate conference and something that a speaker said really stuck with me. The man, talking about being intentional as a salesman said, “If you aren’t uncomfortable, you probably aren’t making real money.” Obviously portfolio management is a bit different than building spheres of influence and making strong sales pitches; however, I do think that it is important for all investors, regardless of management philosophy, to be willing to push his or her boundaries, to make his or her self uncomfortable, all in pursuit of broadened experience and increased knowledge. Like I said before, I sometimes consider making investments in the more speculative names that I will be focusing on in this series in my actual portfolios, though I resist temptation knowing that I don’t likely have the intestinal fortitude required to cope with inherent volatility that comes along with these sorts of investments. Many of the more popular, growth-oriented, momentum-fueled stocks that I plan on targeting within The Home Run Fund have been on my wish list for years. Because of the discipline that I maintain in my personal portfolios and my prioritization of capital preservation, I simply don’t allow myself to invest in these stocks due to rich valuations no matter how much I respect, and even love, the companies themselves. However, looking back I have often regretted this conservative mindset when in hindsight I see that my target prices would have been attractive entry points, eventually leading to big-time gains. I wouldn’t exactly call my reflections on these missed opportunities regret, because I know very well why I didn’t invest in those companies in the first place (they simply didn’t fit into my portfolio’s plan); however, I do think that if I can prove a positive trend with regard to my ability to target attractive entries in less predictable, more volatile names, I would be more willing to put my capital at risk in the markets knowing that my system has proven to be successful in real time and warrants investment attention. To me, experiential knowledge is the best kind. The emotional responses to success and failure leave a much bigger impact and stick with me much longer than most academic study. In other words, “feeling” a loss or gain is much more tangible than simply reading about one or the other. This project will enable me to experience these feelings to a certain extent without putting my capital at risk in the markets. The real-time nature of this portfolio project will help me dial in my evaluation system in areas of the market that are rather foreign to me. Doing it this way should be more effective than simply back testing ideas. Although this “Fund” will be hypothetical, you can rest assured that I will be performing the same level of due diligence when making selections for this portfolio as I do my own. I am too competitive and (shamefully) prideful not to. I want positive results here; I want to prove to myself that I am just as capable of management success in a more speculative environment as I am when really crunching the numbers and patiently waiting for safety margins to widen in the blue chip dividend names. I hope that you all will take this ride with me; with any luck, it’ll be an enjoyable experience for all involved. As always, I look forward to your feedback (probably more so now than ever, because I’ll be dealing with trades in this portfolio that are undoubtedly out of my comfort zone). So, without further adieu, let me introduce the basic ground rules and strategic guidelines for this project: I will be giving myself $100,000 hypothetical dollars to build this portfolio. There will be no new cash added throughout the process. The primary goal of this portfolio is capital appreciation. Unlike my actual portfolios, income will not play a large role in stock selection. All income generated within the portfolio will be pooled in with the cash reserves fund and put to work when making future purchases. I will be comparing this portfolio to all relevant benchmarks in pursuit of Alpha. Unlike my personal portfolios, here I will be focusing more on small/mid cap companies. I will be “buying”, “selling”, and “short-selling” individual stocks or bonds. I will not be using option strategies in this portfolio. I will also not own mutual funds, index funds, close ended funds, exchange traded notes, or the like. I will give myself 30 free trades a month for this fund (the same deal I get at my brokerage); although I doubt I will ever exceed that amount, any trades above the 30 trade threshold will cost $7.99. I say I don’t plan on exceeding that number of trades because I plan on this portfolio being much more highly concentrated than my own. I don’t have set in stone targets with regard to number of holdings or asset allocation. I would like to maintain between 10 and 15 holdings (much less than the 50+ I own in my actual portfolio), though this is subject to change depending on price action and opportunities that arise in the markets. There will be no weighting or section allocation targets within the fund. Being a value investor at heart, I will be looking to capitalize on contrarian moves, more willing to take risks and attempt to catch falling knives here than I am within my actual portfolios. Similar to the portfolios I currently manage I will be looking to own companies with wide competitive moats. However, in The Home Run Fund I will also happily expose myself to companies with very narrow moats assuming that they offer a product or service that I deem to be by and large the best in breed in their industry. I will also be looking to give myself exposure to long-term trends that I believe strongly in. I do this in my actual portfolios as well, though value plays a bigger role than my belief in a trend. In this portfolio I will look past valuations when I truly believe in a movement, especially if it’s expected to play out in the short-term. And lastly, and probably most importantly for this project, I will do my best to check my fear of failure at the door when entering the confines of The Home Run Fund . This fear and reluctance to put my capital at risk has caused me to lose out on potentially lucrative opportunities in the past. I already manage a relatively conservative portfolio, that isn’t the point with this one. I began making purchases for The Home Run Fund last Friday during regular market hours. Just as I did with these purchases, I will be posting stock talks here at SA focused on each purchase/sale. This allows for transparency when it comes to my entry and exit prices. It also allows anyone interested to keep track of moves made by the “fund” in real time giving me time to write and publish detailed trade summaries. Here are the trades I’ve made thus far and a quick snapshot of the portfolio as it sits today. I will briefly describe my reasoning for each selection in this piece, but for the sake of word count, I will be posting primary ticker pieces on each trade made as well, covering my thought process involved in much greater detail later. Starting out the Fund purchasing shares of Alphabet (NASDAQ: GOOGL ) (NASDAQ: GOOG ) and Amazon (NASDAQ: AMZN ) was a relatively easy choice. It’s too bad that I waited until after their recent stellar earnings reports to begin this project. If I had started this a week ago I would have saved a nice chunk of change on these two trades. However, I couldn’t deny myself exposure to these two transformative companies. I think that any portfolio focused on growth should seriously consider holding these two names. Both companies have expanded their business operations to the point that they have their fingers in a myriad of potentially highly profitable cookie jars. I’ve been following both Google and Amazon for some time now and never allowed myself to pull the trigger due to their valuations and lack of dividend payments. Well, even though I’d obviously love to pick up shares here on dips, I decided it was best to simply bite the bullet and initiate positions regardless of current valuations because of the massive growth prospects both companies offer. (click to enlarge) Biogen (NASDAQ: BIIB ) is a company that caught my eye due to recent weakness in the biotech space. Unlike many of its brethren in the Nasdaq Biotech ETF (NASDAQ: IBB ), Biogen is a highly profitable company. Sure, recent question marks have arose that are company specific, but for the most part I think this company has traded down because of industry wide fears sparked in part by politicians posturing on price gouging and drug prices. Even if recent events in the space lead to a restructuring of the pricing models, I simply don’t believe that any changes will be impactful enough to justify the sort of selloff that BIIB has experienced as of late. Also, I am interested in the massive potential that BIIB’s pipeline could have in store, namely in the treatment Alzheimer’s disease, something that has been very difficult and elusive for biotechs thus far. Whole Foods Market (NASDAQ: WFM ) is a company that I own in my personal portfolio. I actually increased my own position by 15% at this $30.75 share price. I love what this company represents. I think the health foods movement is a long-term trend, not a fad. I think science is increasingly pointing towards the fact that humans should be consuming more natural, less processed foods. And, not only this, but I love the experience that WFM stores offer. Shopping there is a pleasure (albeit a relatively more expensive one). I understand that comps are slowing, but I think that store count growth will offset this. I also think that after recent weakness in the health food-focused grocer industry, M&A activity will pick up in the space and WFM could benefit from this, as either an acquirer or an aquiree. I like Blue Buffalo Pet Products (NASDAQ: BUFF ) for many of the same reasons that I like WFM. Just as I think the health foods movement is real and will be long lasting, I think the humanization trend with people and their pets is real as well. I think wholesome, natural pet food products will continue to gain market share within the pet food industry and BUFF is best situated to benefit from this. I like BUFF as a pure play in the space rather than the other larger conglomerate type companies that offer wholesome natural pet foods as a very small part of their overall operations. This company has fallen hard since its unfortunately timed IPO in late July. Shares initiated trading in the $27 range and now $10 cheaper, I find the value much more attractive. GoPro (GRPO) and Ambarella (NASDAQ: AMBA ) trades were announced together because I view both positions in a similar light. First, looking at GoPro I see a company with a best in breed type product that comes with a lot of fanfare. The cameras that this company makes are top notch and I don’t see it losing its spot at the top of the wearable camera space anytime soon. I also wouldn’t be surprised to see GoPro transition into the media space with some of the unique content that its hardware can create. It already has relationships with many of the biggest media and entertainment companies. Original content seems to be all the rage these days and I think as GoPro matures (if it isn’t bought out before then), it will head in this direction. AMBA makes chips for GoPro, though I see this as a more general play on this industry, as well at the drone space, which AMBA has made strides in. With the holiday season coming up, I think we may be in for another GoPro Christmas. Also, I wouldn’t be surprised if drones are one of the more popular presents purchased this year (and in subsequent years as well). Both companies have experienced major weakness over the last several months, bringing their valuations down to much more attractive levels. I know that I’m attempting to catch falling knives here but I think over the long-term I will be rewarded. Here is a snap shot of what the portfolio looks like currently. (click to enlarge) Like I said before, I hope that we’re all able to take something away from this project and put it to use in our own portfolio management practices. I hope you enjoyed this introduction and look forward to all of The Home Run Fund pieces on the way. Please feel free to leave advice, recommendations, or critiques in the comment sections as we move forward. Best of luck all!

MOAT: Have You Considered Using An ETF To Find Companies With Moats?

Summary The sector allocations were a bit surprising to me. Industrials were heavily weighted while utilities and health care were not. The fund has a 15% turnover ratio, which seems within reason for the strategy. The idea of holding attractively priced companies with solid economic moats makes sense, but applying that strategy as an ETF is problematic. The sheer size of the ETF would be a huge problem for acquiring shares in smaller companies with the equal weighting philosophy. Larger companies will receive significantly more coverage and the market should be more efficient. Investors should be seeking to improve their risk adjusted returns. I’m a big fan of using ETFs to achieve the risk adjusted returns relative to the portfolios that a normal investor can generate for themselves after trading costs. One of the funds that I’m researching is the Market Vectors Wide Moat ETF (NYSEARCA: MOAT ). I’ll be performing a substantial portion of my analysis along the lines of modern portfolio theory, so my goal is to find ways to minimize costs while achieving diversification to reduce my risk level. Expense Ratio The net expense ratio for MOAT is .49%. I tend to be very frugal with my expense ratios, so I like to see those low levels. When I’m looking at a simple market cap weighted broad market or total market ETF I would expect to see single digit expense ratios. On the other hand, this portfolio would require analysis on the individual companies so higher expenses would be expected. Sector The following chart breaks down the sector allocations: I don’t love huge allocations to consumer discretionary, but I can believe that they would make sense for a portfolio based on having economic moats since there should be some material differentiation in the products provided by the companies. On the other hand, seeing industrials at almost 25% is quite a surprise to me. Perhaps their concept of a moat is different from mine, but they clearly don’t weight utilities high despite the utilities having regulated monopolies. I would think a monopoly that was protected through regulation would have a fairly solid economic moat. In a similar manner I would have expected stronger allocations to health care because the patent system provides long lasting economic moats. Largest Holdings The following chart shows the largest holdings for the fund from the end of the third quarter: I pulled up the daily list of holdings to verify that they were not materially changed. Since the goal here is to buy companies with durable economic moats, I would expect the allocations to remain similar with some small variations as shares go up and down in value causing them to trade places on the list. (click to enlarge) I had to pull the fund up on Schwab to find the turnover ratio, which was listed at 15%. All in all that suggests the portfolio would be turned over about once every 6 to 7 years. That isn’t too bad. The reason for the turnover seems to be that the portfolio is designed to be allocated as an equal weight portfolio across the “most attractively priced” companies that have been classified as having large moats. If the case is based on most attractively priced, then it starts to seem strange that the companies are not moving up in price enough to force the positions to be turned over the next time the index is updated. Conclusion There is nothing wrong with the concept of selecting stocks based on finding reasonably priced companies that have economic moats to prevent competition from eroding their profits. The strategy makes a great deal of sense and investors selecting individual companies would be wise to consider the influence of future competition on the success of their investment. A challenge for an ETF attempting to follow the same strategy is that it could require some fairly significant capital flows if the ETF becomes larger. The need to completely remove companies and buy up a 5% allocation in another company would risk moving market prices if the ETF were large and their strategy included fairly small companies. While moats may be much more common for established companies that rule their space, that doesn’t mean there won’t be very attractively priced smaller companies that are flying under the radar. The nature of needing to be able to suddenly buy up around $30 million to $40 million would be a difficulty for companies with a market capitalization lower than $1 billion since it could require purchasing at least 3% of the company. This will probably force the ETF to only consider larger companies. The concept makes sense, but execution of the strategy seems like a logistical nightmare unless the investment universe is significantly restricted to limit the list of potential investments to medium and larger companies. Once those restrictions are in place, it seems much more difficult to find and select the best securities because larger capitalization companies attract substantially more analyst attention and should generally be priced be more efficiently.